|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
260,040,000 |
Market
Cap: |
104.57(B) |
Last
Volume: |
1,256,271 |
Avg
Vol: |
1,619,368 |
52
Week Range: |
$323.57 - $446.08 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ-100 |
|
S&P 400 MIDCAP |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 543 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
67,740 |
146,629 |
258,193 |
599,091 |
Total Sell Value |
$28,555,052 |
$59,794,343 |
$99,413,137 |
$200,179,521 |
Total People Sold |
8 |
12 |
15 |
18 |
Total Sell Transactions |
28 |
40 |
68 |
131 |
End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Biller Jonathan |
EVP and Chief Legal Officer |
|
2024-02-12 |
4 |
AS |
$418.77 |
$727,822 |
D/D |
(1,738) |
18,280 |
|
-5% |
|
Atkinson Edward Morrow Iii |
EVP, Chief Technical Ops. Off. |
|
2024-02-12 |
4 |
AS |
$420.24 |
$383,679 |
D/D |
(913) |
23,137 |
|
-5% |
|
Tatsis Ourania |
EVP, Chief Reg. & Quality Off. |
|
2024-02-12 |
4 |
AS |
$420.24 |
$131,955 |
D/D |
(314) |
68,179 |
|
-5% |
|
Altshuler David |
EVP, Global Research and CSO |
|
2024-02-12 |
4 |
AS |
$420.24 |
$1,321,655 |
D/D |
(3,145) |
47,588 |
|
-5% |
|
Ambrose Kristen |
SVP & Chief Accounting Officer |
|
2024-02-12 |
4 |
AS |
$420.24 |
$577,410 |
D/D |
(1,374) |
9,676 |
|
-5% |
|
Sachdev Amit |
EVP Chief Patient & Ext Af Off |
|
2024-02-09 |
4 |
D |
$422.74 |
$854,780 |
D/D |
(2,022) |
77,586 |
|
- |
|
Arbuckle Stuart A |
EVP, COO |
|
2024-02-09 |
4 |
D |
$422.74 |
$1,343,045 |
D/D |
(3,177) |
80,013 |
|
- |
|
Wagner Charles F Jr |
EVP & Chief Financial Officer |
|
2024-02-09 |
4 |
D |
$422.74 |
$1,102,083 |
D/D |
(2,607) |
63,454 |
|
- |
|
Biller Jonathan |
EVP and Chief Legal Officer |
|
2024-02-09 |
4 |
D |
$422.74 |
$671,311 |
D/D |
(1,588) |
20,018 |
|
- |
|
Atkinson Edward Morrow Iii |
EVP, Chief Technical Ops. Off. |
|
2024-02-09 |
4 |
D |
$422.74 |
$351,720 |
D/D |
(832) |
24,050 |
|
- |
|
Bozic Carmen |
EVP and CMO |
|
2024-02-09 |
4 |
D |
$422.74 |
$887,754 |
D/D |
(2,100) |
46,810 |
|
- |
|
Kewalramani Reshma |
CEO & President |
|
2024-02-09 |
4 |
D |
$422.74 |
$3,489,719 |
D/D |
(8,255) |
162,271 |
|
- |
|
Tatsis Ourania |
EVP, Chief Reg. & Quality Off. |
|
2024-02-09 |
4 |
D |
$422.74 |
$887,754 |
D/D |
(2,100) |
68,493 |
|
- |
|
Altshuler David |
EVP, Global Research and CSO |
|
2024-02-09 |
4 |
D |
$422.74 |
$887,331 |
D/D |
(2,099) |
50,733 |
|
- |
|
Ambrose Kristen |
SVP & Chief Accounting Officer |
|
2024-02-09 |
4 |
D |
$422.74 |
$249,839 |
D/D |
(591) |
11,050 |
|
- |
|
Leiden Jeffrey M |
Executive Chairman |
|
2024-02-09 |
4 |
D |
$422.74 |
$3,402,212 |
D/D |
(8,048) |
30,300 |
|
- |
|
Leiden Jeffrey M |
Executive Chairman |
|
2024-02-08 |
4 |
D |
$421.73 |
$1,137,828 |
D/D |
(2,698) |
38,348 |
|
- |
|
Tatsis Ourania |
EVP, Chief Reg. & Quality Off. |
|
2024-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
7,114 |
70,593 |
|
- |
|
Kewalramani Reshma |
CEO & President |
|
2024-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
20,327 |
170,526 |
|
- |
|
Wagner Charles F Jr |
EVP & Chief Financial Officer |
|
2024-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
7,114 |
66,061 |
|
- |
|
Bozic Carmen |
EVP and CMO |
|
2024-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
5,928 |
48,910 |
|
- |
|
Sachdev Amit |
EVP Chief Patient & Ext Af Off |
|
2024-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
7,114 |
79,608 |
|
- |
|
Altshuler David |
EVP, Global Research and CSO |
|
2024-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
7,114 |
52,832 |
|
- |
|
Arbuckle Stuart A |
EVP, COO |
|
2024-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
8,448 |
83,190 |
|
- |
|
Biller Jonathan |
EVP and Chief Legal Officer |
|
2024-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
4,743 |
21,606 |
|
- |
|
1777 Records found
|
|
Page 3 of 72 |
|
|